Drug intelligence / Profile preview

SPC3187

Development stage: Discontinued
Lead developer: Roche
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

SPC3187 is an LNA-based RNA antagonist that was developed for oncology applications. It was part of a collaboration between Santaris Pharma and Enzon Pharmaceuticals, with identified targets including HER3 and β-catenin. The development of SPC3187 was ultimately terminated due to unfavorable preclinical and clinical data.

Targets

CTNNB1 (Beta-catenin)ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on SPC3187.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPC3187.

Explore the full profile